An observational study in Heart Failure, Heart Dilation and Left Ventricular Hypertrophy, sponsored by University Hospital Ostrava. Status unknown at 1 site in Czechia. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-02-14.
Sponsored by University Hospital Ostrava · Observational
Among 165 studies in Heart Failure with a site in Czechia — 35 open to participants now, 43 under way, 14 of them phase 3. Heart Failure · Czechia.
Among the 165 studies in Heart Failure with a site in Czechia, this one is the 19th largest by planned enrollment of the 30 observational ones that give a count, is one of 12 that started in 2018, is one of 30 observational ones, and was the 101st registered.
6,331 studies on the registry are indexed under Heart Failure; 1,396 are open to participants now.
This study's planned enrollment of 200 is close to the median of 200 across 1,983 observational studies indexed under Heart Failure.
Browse Heart Failure studies →35 of the 165 studies in Heart Failure with a site in Czechia are open now, in 12 countries. Each count lists the studies.
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →165 studies; the count open now beside each. This study's row is marked.
First in 1983; this study’s year is marked. 12 started in 2018.
Median enrollment 456 across the 135 interventional studies, 418 across the 30 observational. Of the 112 that completed or were terminated, 63 (56%) have results posted.
139 of 165 have an industry lead sponsor. The 10 most frequent:
University Hospital Ostrava is the lead sponsor of 148 studies on the registry; 50 are open to participants now.
University Hospital Ostrava has 4 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
8 of the studies in Heart Failure with a site in Czechia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
| NCT03093961Corvia MedicalREDUCE LAP-HFREF TRIAL | 2026-12 |
| NCT06331208Institute for Clinical and Experimental MedicineMechanisms of Pulmonary Vascular Dysfunction in Heart Failure | 2026-12-30 |
| NCT06641362VDI TechnologiesUltra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED) | 2027-03 |
Among the 165 studies in Heart Failure with a site in Czechia, from their registry updates:
The aim of the study is to determine the analytical characteristics of the microRNA enzymatic immunoassay (miREIA) method and to determine various relations among miRNA biomarkers and heart failure (HF) with reduced ejection fraction(HFrEF).
The investigators assume that there are correlations between levels of selected miRNA and HFrEF. These correlations provide information to formulate pathophysiological conclusions, which will significantly contribute to early diagnostics and also the treatment of this disease.
Heart failure presents a significant diagnostic and treatment problem. The mortality in the Czech Republic related to this condition is high. The current treatment strategy consists of the administration of medication to patients, in order to attenuate the clinical manifestations of the disease and to influence the overall survival of patients suffering from this condition. Another treatment option is a mini-invasive procedure, with implantation of a pacemaker with biventricular stimulation, or transplantation of the heart. Despite these treatment options, the mortality of patients due to heart failure remains high, and new approaches are being studied for the diagnostics and treatment of heart failure. Factors that may play an important role in earlier diagnostics are miRNA. These molecules are located in the circulating blood. They are being described as suitable prognostic markers of heart failure, which may contribute to earlier diagnostics and bring a better understanding of processes going on in the human body.
In the study, the authors will take blood samples in order to analyze the presence of miRNA. These levels of miRNA will be compared with heart ultrasound parameters of HF patients and healthy control subjects.
Patients with known stable heart failure hospitalized or followed at the outpatient clinic at the University Hospital Ostrava, Department of Cardiovascular Diseases.
The control group consists of healthy individuals, who had volunteered for the study.
Inclusion criteria (patient group):
Inclusion criteria (control group):
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients indicated for biochemical analysis due to a suspected heart disease, with HFrEF diagnosed on echocardiography with left-ventricular ejection fraction lower than 35%. Diagnostic Test: MicroRNA test. Laboratory analysis for the detection of microRNA in blood samples. Diagnostic Test: Heart ultrasound examination. Heart ultrasound examination will be performed as a standard cardiology examination.
Diagnostic Test: microRNA test · Diagnostic Test: Heart ultrasound examination
Patients with no known heart disease (hypertrophy or dilatation), which has been confirmed on echocardiography. Diagnostic Test: microRNA test. Laboratory analysis for the detection of microRNA in blood samples. Diagnostic Test: Heart ultrasound examination. Heart ultrasound examination will be performed as a standard cardiology examination.
Diagnostic Test: microRNA test · Diagnostic Test: Heart ultrasound examination
Laboratory analysis for the detection of microRNA in blood samples.
Heart ultrasound examination will be performed as a standard cardiology examination.
Levels of miRNA (in pmol/L)
Full blood samples will be taken in both groups after period of clinically stable state and analyzed for levels of miRNA(hsa-miR-21-5p; hsa-miR-23a-3p; hsa-miR-142-5p; hsa-miR-126-3p) with biochemical microRNA enzymatic immunoassay. Measured levels of listed four miRNAs will be provided pmol/L. These levels will be statistically analyzed and compared between patient and control group.
Time frame: 43 months
Correlation between miRNA levels and 1-year mortality and risk of rehospitalization
We will examine levels of miRNA in corelation to 1-year mortality and risk of rehospitalization acquired from Czech national registry (UZIS).
Time frame: 43 months
Plan to share: No — The investigators do not plan to make individual participant data available to other researchers.
Ran from Jun 2018 to primary completion in Dec 2022, 54 months.
Of 793 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 99. This study's 54 months is above that.
Counting every sponsor, half of 975 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.